Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Tradipitant

Generic Name: Tradipitant

Drug Type: Small Molecule

Chemical Formula: C_₂₈H_₁₆ClF_₆N_₅O

CAS Number: 622370-35-8

Unique Ingredient Identifier: NY0COC51FI

Overview

Tradipitant has been used in trials studying the treatment and prevention of Eczema, Pruritus, Gastroparesis, Chronic Pruritus, and Atopic Dermatitis, among others.

Background

Tradipitant has been used in trials studying the treatment and prevention of Eczema, Pruritus, Gastroparesis, Chronic Pruritus, and Atopic Dermatitis, among others.

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

Effects of Tradipitant on Satiation, Gastric Volume, Gastric Accommodation, and Gastric Emptying in Healthy Volunteers

Phase 1

Completed

Posted: 2021/04/19

Sponsor:Vanda Pharmaceutical...

ID:NCT04849559

Single-Patient Expanded Access Protocol for Tradipitant In A Single Patient With Gastroparesis

Posted: 2020/07/17

Sponsor:Vanda Pharmaceutical...

ID:NCT04474990

Motion Syros: A Study to Investigate the Efficacy of Tradipitant in Subjects Affected by Motion Sickness

Phase 3

Completed

Posted: 2020/03/31

Sponsor:Vanda Pharmaceutical...

ID:NCT04327661

ODYSSEY: A Study to Investigate the Efficacy of Tradipitant in Treating Severe or Critical COVID-19 Infection

Phase 3

Posted: 2020/03/30

Sponsor:Vanda Pharmaceutical...

ID:NCT04326426

Evaluating the Effects of Tradipitant vs. Placebo in Atopic Dermatitis (EPIONE2)

Phase 3

Terminated

Posted: 2019/10/28

Sponsor:Vanda Pharmaceutical...

ID:NCT04140695

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

No Singapore products found for this drug

Related News

Vanda Pharmaceuticals Appeals to Supreme Court Over FDA's Fast-Track Denial for Gastroparesis Drug

13 hours ago

Vanda Pharmaceuticals has petitioned the U.S. Supreme Court to overturn the FDA's decision denying fast-track approval for tradipitant, its gastroparesis treatment candidate.

Federal Circuit Upholds Pfizer's Victory in Gene Therapy Patent Dispute for Hemophilia Treatment

17 hours ago

The Federal Circuit has affirmed the Patent Trial and Appeal Board's decision invalidating two patents covering experimental gene therapy for hemophilia treatment, handing Pfizer a significant legal victory.

FDA Budget Cuts Linked to Drug Approval Delays as Small Biotech Faces PDUFA Postponement

24 days ago

Recent government efficiency cuts at the FDA appear to be causing delays in drug approval timelines, with 66% of healthcare professionals surveyed expressing concern about potential PDUFA date postponements.

Vanda Pharmaceuticals Battles FDA Over Gastroparesis Drug Hearing Delays

a month ago

Vanda Pharmaceuticals has accused FDA officials of unlawfully delaying a hearing on its gastroparesis drug tradipitant, claiming the agency is using recent staff reductions as a false excuse for a six-month postponement.

Advancements in Acute Lymphocytic Leukemia (ALL) Treatment Landscape

5 months ago

The FDA approved obecabtagene autoleucel (Aucatzyl) for adults with relapsed or refractory B-cell precursor ALL, marking a significant advancement in CAR T-cell therapy.

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Home Terms & Conditions Privacy Policy